Last reviewed 2026-04-20 · How we verify

Geographical region 1 Entyvio

Alvotech Swiss AG · Phase 1 active Biologic Quality 0/100

Geographical region 1 Entyvio is a Biologic drug developed by Alvotech Swiss AG. It is currently in Phase 1 development.

At a glance

Generic name	Geographical region 1 Entyvio
Sponsor	Alvotech Swiss AG
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study to Investigate Comparative Pharmacokinetics, Safety, Immunogenicity and Tolerability Between AVT80 and Entyvio (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Geographical region 1 Entyvio CI brief — competitive landscape report
Geographical region 1 Entyvio updates RSS · CI watch RSS
Alvotech Swiss AG portfolio CI

Frequently asked questions about Geographical region 1 Entyvio

What is Geographical region 1 Entyvio?

Geographical region 1 Entyvio is a Biologic drug developed by Alvotech Swiss AG.

Who makes Geographical region 1 Entyvio?

Geographical region 1 Entyvio is developed by Alvotech Swiss AG (see full Alvotech Swiss AG pipeline at /company/alvotech-swiss-ag).

What development phase is Geographical region 1 Entyvio in?

Geographical region 1 Entyvio is in Phase 1.

Manufacturer: Alvotech Swiss AG — full pipeline
Compare: Geographical region 1 Entyvio vs similar drugs
Pricing: Geographical region 1 Entyvio cost, discount & access